银杏叶(Ginkgo Biloba leaves Extract) - 药物靶点：NOS2_在研适应症：神经系统疾病，阿尔茨海默症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Gingogink、Ginkgo biloba special extract、EGB 761

+ [2]

靶点

NOS2

作用机制

NOS2抑制剂(诱导型一氧化氮合酶抑制剂)、血小板聚集抑制剂

治疗领域

神经系统疾病

在研适应症

神经系统疾病阿尔茨海默症

非在研适应症-

原研机构

Ipsen Pharma SAS

在研机构

Ipsen SAIpsen Pharma SAS

非在研机构-

最高研发阶段批准上市

首次获批日期

法国 (2002-02-28),

阿尔茨海默症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C11H13ClN2S

InChIKeyLAZPBGZRMVRFKY-HNCPQSOCSA-N

CAS号16595-80-5

关联

9

项与银杏叶相关的临床试验

NCT03216681

/ CompletedN/A

An Observational, Open Label, Post Marketing Study to Evaluate the Safety and Effectiveness of Hoat Huyet Nhat Nhat Compared With Gingko Biloba EGb761 (Tanakan 40mg) in Patients With Symptoms Related to the Insufficient Blood Supply to the Brain

The purpose of this study is to evaluate the effectiveness of Hoat Huyet Nhat Nhat on the reduction of common symptoms related to the insufficient blood supply to the brain such as headache, vertigo, dizziness, sleep disorders and forgetfulness; compared with Gingko Biloba Egb761 (Tanakan) after 45 days of treatment

开始日期2017-07-01

申办/合作机构

Nhat Nhat Pharmaceutical Co.，Ltd

NCT02321475

/ CompletedN/A

Non-interventional Prospective Observational Study to Describe EGB 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders.

The purpose of this study is to determine the effectiveness of EGb 761® (Tanakan®) in Russian patients of middle age and younger, suffering from psycho-emotional symptoms added to cognitive disorders based on the improvement of FAM test (feeling-healthy, activity, mood test) score.

开始日期2014-06-01

申办/合作机构

Ipsen SA

NCT00814346

/ Completed临床2期

Effect of Oral EGb761® on Brain Glucose Metabolism in Three Groups of Elderly With Memory Complaint, Mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, Randomised, Double-blind, Parallel Groups, Placebo-controlled Study

The aim of the study is to evaluate the effect of EGb761®, in comparison to placebo, on cerebral glucose metabolism, in three groups of elderly patients: newly diagnosed mild Alzheimer's disease (AD), memory complaint patients with cognitive impairment (MC) and memory complaint patients cognitively normal (CNE). The first phase includes four weeks treatment with EGb761® for all groups, with change in brain glucose metabolism at month 1 using 18 FDG-PET, as primary endpoint which will be followed by an open 17 months follow-up (FU) period with EGb761® treatment in MC and CNE patients.

开始日期2008-10-01

申办/合作机构

Ipsen SA

100 项与银杏叶相关的临床结果

登录后查看更多信息

100 项与银杏叶相关的转化医学

登录后查看更多信息

100 项与银杏叶相关的专利（医药）

登录后查看更多信息

7

项与银杏叶相关的文献（医药）

2009-09-01·Pharmazie in unserer Zeit

Grundlagen der therapeutischen Anwendung von EGb 761^®. Wirkung auf die Kraftwerke der Zellen

Review

作者: Christian J. Fehske ; Kristina Leuner ; Walter E. Müller ; Reham M. Abdel‐Kader

2009-09-01·Pharmazie in unserer Zeit

Chemie, Pharmakokinetik und Metabolismus von Ginkgo‐Extrakt. Eines der bestuntersuchten Phytopharmaka

Review

作者: Alexander Paulke ; Manfred Schubert-Zsilavecz ; Christian Ude ; Mario Wurglics

100 项与银杏叶相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
神经系统疾病	中国	Ipsen Pharma SAS	2007-03-09
阿尔茨海默症	法国	Ipsen SA	2002-02-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00010803 (GEM, CTgov)	临床3期	阿尔茨海默症	3,069	Ginkgo biloba (Ginkgo Biloba)	衊願積糧繭鹹觸鬱獵觸(襯糧淵選餘顧選繭膚鹹) = 築窪繭醖壓構憲淵衊簾醖餘糧積壓顧構膚獵製 (鏇膚鹽衊艱艱積鬱製窪, 簾壓餘壓淵窪積鏇獵齋 ~ 壓構鬱衊淵壓廠構衊鏇) 更多	-	2010-09-16
				Placebo (Placebo)	衊願積糧繭鹹觸鬱獵觸(襯糧淵選餘顧選繭膚鹹) = 積觸齋築醖膚艱選網構醖餘糧積壓顧構膚獵製 (鏇膚鹽衊艱艱積鬱製窪, 鏇鏇廠廠齋壓獵遞製鹽 ~ 繭簾醖鏇鑰遞衊製鏇範) 更多
AAIC2008	N/A	阿尔茨海默症 \| 血管性痴呆	410	Ginkgo biloba extract EGb 761® 240 mg	襯願鏇醖顧淵淵構遞構(遞衊鬱齋選簾構餘積獵) = 遞顧窪構衊壓衊簾鬱齋糧餘齋壓鏇艱淵繭襯網 (構鹽築觸蓋構獵觸淵餘 ) 更多	积极	2008-07-01
				Placebo	襯願鏇醖顧淵淵構遞構(遞衊鬱齋選簾構餘積獵) = 遞廠製顧餘積鬱衊糧蓋糧餘齋壓鏇艱淵繭襯網 (構鹽築觸蓋構獵觸淵餘 ) 更多